z-logo
Premium
Utility of cystatin C to monitor renal function in duchenne muscular dystrophy
Author(s) -
Viollet Laurence,
Gailey Susan,
Thornton David J.,
Friedman Neil R.,
Flanigan Kevin M.,
Mahan John D.,
Mendell Jerry R.
Publication year - 2009
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.21420
Subject(s) - duchenne muscular dystrophy , cystatin c , medicine , renal function , creatinine , biomarker , endocrinology , cystatin , nephrotoxicity , population , neuromuscular disease , muscular dystrophy , urology , kidney , disease , chemistry , biochemistry , environmental health
Creatinine as a marker of renal function has limited value in Duchenne muscular dystrophy (DMD) because of reduced muscle mass. Alternative methods of assessing renal function are sorely needed. Cystatin C, a nonglycosylated protein unaffected by muscle mass, is potentially an ideal biomarker of nephrotoxicity for this population but requires validation. In all, 75 subjects were recruited: 35 DMD (mean age 10.8 ± 5.4 years, corticosteroids n = 19, ambulatory n = 26), 29 healthy controls, 10 with renal disease, and one DMD with renal failure. Cystatin C levels in DMD were normal irrespective of age, ambulation, or corticosteroid treatment. Serum cystatin C was 0.67 ± 0.11 mg/l compared to normal controls 0.69 ± 0.09. mg/l. In these same individuals serum creatinine was severely reduced (0.27 ± 0.12 mg/dl) versus normals (0.75 ± 0.15 mg/dl, P < 0.01). In one DMD subject in renal failure, cystatin C was elevated. This study demonstrates the potential value of cystatin C as a biomarker for monitoring renal function in DMD. Its applicability extends to other neuromuscular diseases. Muscle Nerve, 2009

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here